Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome.

Medicine - 23 Jan 2026

Wang Qilin, Zeng Beilei, You Chuanyu, Xu Tian, Chen Xinyu, Yang Xueping, Ye Juncai, Gui Yan

Abstract excerpt

RATIONALE: epidermal growth factor receptor (EGFR) mutations play a pivotal role in non-small cell lung cancer (NSCLC), with the EGFR exon 20 insertion (EGFR20ins) mutation being the third most prevalent alteration in the EGFR gene. Patients harboring this mutation typically exhibit a greater tumor burden and poorer overall prognosis. This mutation is strongly associated with resistance to EGFR-TKIs, presenting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutagenesis, Insertional

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41578514
DOI: 10.1097/MD.0000000000046998
PMCID: PMC12851707

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome.PMID 41578514Read ↗

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancerSemantic proximity Read ↗

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.Semantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.Semantic proximity Read ↗

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.Semantic proximity Read ↗

Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.Semantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the ArtSemantic proximity Read ↗

Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

[EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.